According to the statistical analysis of China Bio (Sinopharm Zhongsheng) of Sinopharm Group, the safety of its Beijing company COVID-19 inactivated vaccine is good. After two doses of immunization, all the vaccinated people in the vaccine group produced high titer antibodies, and the positive conversion rate of neutralizing antibodies was 99.52%.
The protective effect (coronavirus pneumonia-19) of Zhongshengjing vaccine on diseases caused by infection in COVID-19 was 79.34%, and the data met the requirements of the relevant technical standards of the World Health Organization and the relevant standards in the Guiding Principles for Clinical Evaluation of Preventive Vaccines in novel coronavirus (Trial) issued by the State Medical and Drug Administration.
According to experts' description, the vaccine protection rate in COVID-19 is 79.34%. Even compared with the mRNA vaccine, it is a good result.
In addition, on May 7th, the World Health Organization (WHO) announced that the COVID-19 inactivated vaccine of China Sinopharm Zhongsheng Company had passed the WHO emergency use certification.
2. Inactivated vaccine of COVID-19 from Wuhan Institute of Traditional Chinese Medicine.
The mid-term analysis data of the third phase clinical trial of COVID-19 vaccine released by China Institute of Biology of Sinopharm Group showed that the inactivated vaccine in COVID-19 was safe after inoculation. After two doses of immunization program, the vaccinators all produced high titer antibodies, and the positive conversion rate of neutralizing antibodies was 99.06%.
The protective effect (coronavirus pneumonia-19) of China biological products vaccine of Sinopharm Group on diseases caused by COVID-19 infection is 72.5 1%, and the data results meet the requirements of the relevant technical standards of the World Health Organization and the "Guidelines for Clinical Evaluation of Preventive Vaccines in novel coronavirus (Trial)" issued by the State Medical and Drug Administration.
3. Beijing Kexing Zhong Covid-19 Inactivated Vaccine
The inactivated COVID-19 vaccine of Kexing Zhongwei is called Kelaifu. The vaccine entered the first and second clinical studies in April 2020, and the safety and effectiveness of the vaccine were confirmed through research.
Phase III clinical studies in Brazil and Turkey evaluated the protective effect of Kelaifu in high-risk population (medical staff receiving pneumonia patients in COVID-19) and general population respectively. Both countries adopted a multicenter, randomized, double-blind, placebo-controlled parallel design. The primary end point was the incidence of diseases caused by COVID-19 after 2 doses of vaccine or placebo 14 days.
Beijing Kexing Zhongwei Biotechnology Co., Ltd. announced the data of the third phase clinical study of the inactivated novel coronavirus vaccine Kelaifu. The results showed that the protective efficacy of the vaccine against diseases caused by COVID-19 was over 50%, and the highest was 9 1.25%.
According to the latest news in May 1 1, the safety and effectiveness of Kexing Zhongxing Weiguan vaccine have been verified in the first quarter of this year.
4. Kangxinuo recombinant COVID-19 vaccine (adenovirus type 5)
The adenovirus vector COVID-19 vaccine produced by Kangxinuo has the characteristics that only 1 needle can activate humoral immunity and cellular immunity. The potential advantages of adenovirus vector system in vaccine development are proved by its stable existence at 2-8℃ and easy storage and transportation.
The mid-term analysis of the third phase clinical trial showed that the overall protective effect of the vaccine on all symptoms was 65.28% after 28 days of single needle inoculation. After single-dose inoculation/0/4 days, the overall protective effect of vaccine on all symptoms was 68.83%. After 28 days of single-needle vaccination, the protective effect of vaccine on severe diseases was 90.07%. 95.47% after single needle inoculation 14 days.
5. zhifei Biorecombinant Subunit Vaccine.
According to the world famous medical journal The Lancet-Infectious Diseases, the recombinant protein subunit vaccine (ZF200 1) 1 developed by zhifei, Anhui Province, and the results of phase 2 clinical trials show that the vaccine is safe.
Most subjects did not observe adverse reactions or mild or moderate adverse reactions, such as redness, pain and itching at the injection site, which are common reactions after recombinant protein vaccine inoculation. No vaccine-related serious adverse events occurred.
The data show that 76% of people can produce neutralizing antibodies after ZF200 1 is inoculated with two doses of vaccine. After three doses of vaccine, 97% people can produce neutralizing antibodies. The geometric mean titer (GMT) of the antibody reached 102.5, which exceeded the neutralizing antibody level of 89 serum samples of recovered patients in COVID-19.
The above content source: Guangming. Com- What are the differences between the five COVID-19 vaccines in China?